SAN DIEGO, Nov. 20 Cyntellect, a privately-held lifesciences company leading the development and commercialization of live cellanalysis, manipulation and purification systems, announced today that it hasentered a research collaboration agreement with the University of FloridaInterdisciplinary Center for Biotechnology Research. The agreement will focuson a variety of research areas including the purification and analysis ofcancer stem cells (CSCs), rare cells which are believed to be directlyinvolved in propagating cancers. The collaboration will exploit Cyntellect'sproprietary LEAP system to purify these CSCs and their progeny withoutdisturbing them from their growing environment -- a feat that should improvescientists' ability to study the natural properties and responses of thesecells. Under the agreement, University of Florida will gain access to LEAPand Cyntellect will receive certain payments and commercial rights todiscoveries under the collaboration.
"We are very pleased to embark with University of Florida on this quest togain a better understanding of the molecular machinery, signaling pathways andmarkers associated with rare cells, such as CSCs. This information will beparamount to innovating novel drug development strategies and developing newcutting-edge diagnostics for crippling diseases, such as cancer," stated Dr.Fred Koller, Cyntellect's Chief Executive Officer. "We believe our LEAPtechnology offers a truly unique, efficient and highly accurate means ofisolating rare cells and making them readily available for subsequentfunctional, proteomic or genetic analyses."
CSCs are cancer cells (found within tumors or hematological cancers) thatpossess characteristics associated with normal stem cells, specifically theability to give rise to all cell types found in a particular cancer sample.These cells are therefore tumorigenic (tumor-forming), perhaps in contrast toother non-tumorigenic cancer cells. CSCs may generate tumors through the stemcell processes of self-renewal and differentiation into multiple cell types.Such cells are proposed to persist in tumors as a distinct population andcause relapse and metastasis by giving rise to new tumors. Therefore,development of specific therapies targeted at CSCs holds hope for improvementof survival and quality of life of cancer patients, especially for sufferersof metastatic disease [Wikipedia].
The collaboration represents the Company's second major LEAP collaborationthis year and follows on the heels of a publicly announced LEAP systempurchase by the University of Florida McKnight Brain Institute earlier thisyear. Cyntellect plans to enter into additional LEAP collaborations in 2009aimed at leveraging cell manipulation for the purpose of enhancing discoveryof new drugs, empowering cell-based diagnostics and accelerating developmentof cellular therapies. Parties interested in being considered for suchcollaborations should initiate contact and submit concept proposals toCyntellect at email@example.com.
Cyntellect, Inc. is a life sciences company committed to revolutionizingthe use of living cells in life science research and cellular therapy. TheCompany combines expertise in high-speed cellular analysis and laser-basedmanipulation to provide products that enable novel cell imaging, purification,and transfection capabilities to enhance the productivity of laboratoryresearch, recombinant protein production, high-content cellular assays,functional genomics and proteomics, and cell purification, includingprocessing of cells for therapeutic transplantation. For additionalinformation please visit the Company's web site at http://www.cyntellect.com.
SOURCE Cyntellect, Inc.